$0.00
$4.40
bear $0.00
base $0.00
bull $4.40
margin of safety $0.50
market price* $7.10
Business condition attached to the margin of safety
Two consecutive quarters where operating cash flow, after subtracting stock-based compensation and capital spending, is positive without new borrowing.
Evolus sells two aesthetic injectables to physicians: Jeuveau, a botulinum toxin (a Botox competitor, made for Evolus by Daewoong in South Korea), and, since April 2025, Evolysse hyaluronic acid fillers (made by Symatese). 2025 revenue was $297.2 million, up 11.6%, with a 66% gross margin. But the business has never produced cash for its owners. Operating cash flow was negative in every year since launch, and after subtracting stock compensation, which we treat as a real cost, and capital spending, owner earnings were about -$0.57 to -$1.40 per share each year from 2020 to 2025. Our reference level is the 2023-2025 median of about -$0.69 per share (roughly -$44 million a year). 2025 was slightly worse than 2024 (-$0.69 versus -$0.57), mainly because receivables and inventory grew by about $11 million each with the Evolysse launch. We therefore assume no improvement in the first year beyond what has already been demonstrated. What has improved: the operating loss narrowed from $49.2 million in 2023 to $32.7 million in 2025, and in the first half of 2026 it was $11.4 million versus $25.4 million a year earlier. Revenue rose to $157.2 million from $137.9 million, while selling, general and administrative expense fell to $109.0 million from $113.3 million after the cost restructuring of the third quarter of 2025. Even so, over the twelve months to June 2026 the operating loss was still about $18.7 million and interest was about $16.2 million, so the business still loses money after paying its lenders. Debt matters here. Borrowings were $150 million at the end of 2025 and $160 million at June 30, 2026, at SOFR (3.5% floor) plus 5%, against $45.2 million of cash. The company also has a $30 million asset-based revolver signed in March 2026 and up to $100 million of further term-loan capacity that must be elected by December 31, 2026. Management states current resources cover the next twelve months. Other fixed claims on the business: a mid-single-digit-percent royalty to Medytox on Jeuveau sales through September 16, 2032 (from a 2021 litigation settlement), and a low-single-digit royalty to the company's founders through mid-2029. The Jeuveau supply and license agreement with Daewoong renewed for three years from September 30, 2023 and renews again only if performance requirements are met, which management expects. Bear case: owner earnings stay near the -$44 million a year level. The company can fund that for a few years from its cash and borrowing capacity, but nothing named in the filings ends the burn, and the lenders come first. Equity is worth $0 per share. On the earnings the company has actually demonstrated, it does not cover its roughly $160 million of borrowings. Base case: the improvement seen in the first half of 2026 is real but the business still loses money after interest, and growth from new products, new markets or share gains is not something we can credit as already secured. Revenue and costs are held at current levels, which leaves owner earnings negative, funded by debt. Shareholders would not be expected to fund those losses, so the value is $0 per share. Evolysse's European launch (planned for the second quarter of 2026) and the expected US approval of Evolysse Sculpt in the second half of 2026 are left out because they have not yet produced results. Bull case: the company's own levers work. Revenue grows 10% a year for five years (below the 11.6% achieved in 2025, on the Evolysse launches and continued Jeuveau sales), while total operating costs rise only 3% a year, consistent with the flat-to-lower spending seen in the first half of 2026. Owner earnings move from about -$14 million in 2027 to about $65 million in 2031, are held there through 2036, and nothing is assumed afterwards. That is worth about $4.40 per share on roughly 66 million shares, discounted at 6%. What would make this wrong: the case is most sensitive to whether spending stays flat as revenue grows. If it does and revenue keeps growing at 10%, the bull outcome is plausible; if the first-half improvement reverses, or if the Daewoong agreement is not renewed on its current terms, value falls short even of that. Accounting note: stock compensation of about $21 million a year and interest are treated as real costs; amortization of the distribution right is a non-cash charge and is not deducted separately. The company is not a going-concern case; the filing carries no substantial-doubt language and management reports adequate liquidity for twelve months. Because only the latest filings were used, we could not reconcile the sales split by country from the filing text.